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Abstract: Febrile seizure (FS) is related to a febrile illness (temperature > 38 ◦C) not caused by
an infection of central nervous system, without neurologic deficits in children aged 6–60 months.
The family study implied a polygenic model in the families of proband(s) with single FS, however in
families with repeated FS, inheritance was matched to autosomal dominance with reduced disease
penetrance. A 20 month-old girl showed recurrent FS and afebrile seizures without developmental
delay or intellectual disability. The seizures disappeared after 60 months without anti-seizure
medication. The 35 year-old proband’s mother also experienced five episodes of simple FS and two
episodes of unprovoked seizures before 5 years old. Targeted exome sequencing was conducted
along with epilepsy/seizure-associated gene-filtering to identify the candidate causative mutation.
As a result, a heterozygous c.2039A>G of the ADGRV1 gene leading to a codon change of aspartic acid
to glycine at the position 680 (rs547076322) was identified. This protein’s glycine residue is highly
conserved, and its allele frequency is 0.00002827 in the gnomAD population database. ADGRV1
mutation may have an influential role in the occurrence of genetic epilepsies, especially those with
febrile and afebrile seizures. Further investigation of ADGRV1 mutations is needed to prove that it is
a significant susceptible gene for febrile and/or afebrile seizures in early childhood.
Keywords: ADGRV1 mutation; familial febrile seizure 4; afebrile seizure; febrile seizure; targeted
exome sequencing
1. Introduction
The international League Against Epilepsy defined febrile seizures (FSs) as a seizure occurring in
children aged 6 to 60 months related to a febrile illness (temperature > 38 ◦C) not caused by an infection
of the central nervous system (CNS), without previous afebrile seizures or neurologic deficits [1,2].
The mean prevalence of FS in children aged 6–60 months according to hospital visit rates in South Korea
was 6.92% (6.12% for girls; 7.67% for boys) during the period 2009–2013 [3]. About a third of patients
with experience of FS will have a second attack, and 50% of those will have a third episode. Past history
of FS during childhood has been reported in 5 to 15% of epileptic patients, with a higher risk of
evolving epilepsy found in children < 14 years with preceding complex FS [4]. The risk of unprovoked
seizures is 5 to 7 times higher in children who experience FS compared to the general population and is
estimated to be 2 to 5% [5,6]. Prolonged FS and febrile status epilepticus are considered as potential risk
Children 2020, 7, 144; doi:10.3390/children7090144 www.mdpi.com/journal/children
Children 2020, 7, 144 2 of 9
factors in subsequently developing epilepsy [7]. Simple FS seem to be genetically complex disorders
affected by variations in several susceptibility genes [8]. Children with a familial history of FS show a
three-fold or higher risk of recurrence than the general population experiencing FSs. A positive familial
history within first-degree relatives is regarded as a compatible risk factor for recurrent FSs than recent
infections, fever, and perinatal exposure [9,10]. The family study implied a polygenic model in families
of proband(s) with a single FS, however, in the families with repeated FSs, the inheritance was matched
to autosomal dominance with reduced disease penetrance [11].
To date, the genetic heterogeneity of familial FSs (termed FEB1–FEB11) has been described in
different studies [12–25]. Particularly, ADGRV1 (OMIM *602851) encoding adhesion G protein–coupled
receptor (aGPCR) V1, a large calcium-binding protein widely expressed in the CNS, was previously
reported as a genetic cause of afebrile and febrile seizures [26]. In this study, targeted exome sequencing
was conducted along with epilepsy/seizure-associated gene-filtering to identify the candidate causative
mutation in a Korean family with febrile and afebrile seizures.
2. Case Presentations
A 20 month-old girl (II-2 in Figure 1a) was referred to the department of pediatric neurology after
four episodes of FS. Her mother witnessed generalized tonic–clonic seizures that lasted under 5 min
with a fever of 38 ◦C–40 ◦C. By the time the patient was transported to the emergency department,
she had fully recovered. At 21 months of age, she came to our emergency department after generalized
tonic–clonic seizure that lasted for 20 min without fever. The seizure had ceased and her mental
state had recovered when she arrived at the emergency room. Two hours later, her seizure recurred
and the seizure was terminated after an injection of lorazepam. In brain magnetic resonance images
(MRI), no obvious abnormalities for her age including an appropriate myelination pattern were
observed (Figure 1b). The interictal electroencephalogram (EEG) was normal (Figure 1c). The results
of metabolic laboratory testing including plasma amino acid, thyroid function tests, lactate/pyruvate,
urine organic acid, and blood gases were normal. We observed her without anti-seizure medication
at the outpatient clinic. After that, she showed two more simple FSs at the age of 24 months and
35 months. At 36 months old, she was admitted because of a prolonged FS. The seizure apparently
lasted for 25 min and ceased after the administration of intravenous lorazepam in the emergency
department. Later, a fever of 39.5 ◦C was noted, and adenoviral infection was diagnosed. Her growth
and developmental milestones were proper for her age. Her height (92 cm), weight (13 kg), and head
circumstance (47 cm) were 50 percentiles, respectively. Febrile and afebrile seizures had not occurred
after the age of 3 and her development was appropriate for her age. Except for a history of seizures in
her mother (I-2 in Figure 1a), there was no family history of developmental delay, intellectual disability,
and epilepsy. The 35 year-old proband’s mother experienced five episodes of simple FS and two
episodes of unprovoked seizures before 5 years old. The mother’s computed tomography scan and
EEG were normal and she has remained seizure free since 5 years old without anti-seizure medication.
The mother’s development was completely normal and she completed her college education.
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Figure 1. (a) Pedigree of a Korean family with afebrile (light grey) and febrile seizures (dark grey) carrying 
ADGRV1 mutation. (b) Brain magnetic resonance imaging was done at the age of 2 in the proband. No abnormal 
signal intensity or enhanced lesion in the brain parenchyma was seen. No evidence of abnormal finding in the 
diploic space and cerebrospinal fluid space. (c) Interictal electroencephalogram was normal tracing at the age of 
2 in the proband. Focal abnormalities, persistent asymmetries, and potentially epileptogenic discharges were not 
seen. 
3. Molecular Analysis 
3.1. Targeted Exome Sequencing 
The study protocol was approved by the Institutional Review Board of the Catholic University of Korea. 
Written informed consent was collected from the parents on behalf of their children for the publication of 
recognizable data or images included in this report before the blood sampling, and clinical data were obtained 
from the proband and her parents. To resolve the potential genetic cause, the genomic DNA of the proband was 
studied by targeted exome sequencing using TruSight One Sequencing Panel (Illumina, Inc., San Diego, CA, 
USA), which covers rare inherited disease-associated regions of the exome with a comprehensive coverage of > 
4800 disease-associated genes. Massively parallel sequencing was conducted using the Illumina HiSeq2500 
(Illumina, Inc.) to generate paired-end reads of 150 nucleotides. Exome sequences were estimated for all modes 
of inheritance and the variants filtered initially for rare variants (allele frequency < 0.01) from the public 
sequence databases (gnomAD, https://gnomad.broadinstitute.org). The remaining base change and small indels 
located on epilepsy/seizure-associated genes were selected according to web-based genetic databases (OMIM, 
https://www.omim.org/; ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/). The candidate missense mutations 
were estimated to be pathogenic or have a damaging effect by in silico analysis for conservation level as well as 
for functional effect. 
3.2. mRNA Expression Analysis for ADGRV1 Mutation 
To determine the pathogenicity of the candidate ADGRV1 mutation, quantitative reverse transcription 
polymerase chain reaction (RT-PCR) was performed with complementary DNA synthesized from RNA isolated 
from whole blood on a CFX96™ Real Time PCR Detection System (BioRad, Hercules, CA, USA) using the 5′ 
reporter FAM™ dye-labeled and 3′ quencher Minor groove binder (MGB)-labeled probes (Applied Biosystems, 
Foster City, CA, USA). Gene expression level was normalized to GAPDH endogenous control and analyzed 
Figure 1. (a) Pedigree of a Kore n family with afebrile (li ht grey) and febrile seizures (dark grey)
carrying ADGRV1 mutation. (b) Brain magnetic resonance imaging was done at the age of 2 i
the proband. No abnormal sig al intensity or en anced lesion in the brai parenchyma was seen.
No evidence of abnormal finding in the diploic space and cerebrospinal fluid space. (c) Interictal
electroencephalogram was normal tracing at the age of 2 in the proband. Focal abnormalities, persistent
asymmetries, and potentially epileptogenic discharges were not seen.
3. Molecular Analysis
3.1. Targeted Exome Sequencing
The study protocol was approved by the Institutional Review Board of the Catholic University of
Korea. Written informed consent was collected from the parents on behalf of their children for the
publication of recognizable data or images included in this report before the blood sampling, and clinical
data were obtained from the proband and her parents. To resolve the potential genetic cause, the genomic
DNA of the proband was studied by targeted exome sequencing using TruSight One Sequencing
Panel (Illumina, Inc., San Diego, CA, USA), which covers rare inherited disease-associated regions
of the exome with a comprehensive coverage of > 4800 disease-associated genes. Massively parallel
sequencing was conducted using the Illumina HiSeq2500 (Illumina, Inc.) to generate paired-end
reads of 150 nucleotides. Exome sequences were estimated for all modes of inheritance and the
variants filtered initially for rare variants (allele frequency < 0.01) from the public sequence databases
(gnomAD, https://gnomad.broadinstitute.org). The remaining base change and small indels located on
epilepsy/seizure-associated genes were selected according to web-based genetic databases (OMIM,
https://www.omim.org/; ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/). The candidate missense
mutations were estimated to be pathogenic or have a damaging effect by in silico analysis for
conservation level as well as for functional effect.
3.2. mRNA Expression Analysis for ADGRV1 Mutation
To determine the pathogenicity of the candidate ADGRV1 mutation, quantitative reverse
transcription polymerase chain reaction (RT-PCR) was performed with complementary DNA
synthesized from RNA isolated fro whole blood on a CFX96™ Real Time PCR Detection System
(BioRad, Hercules, CA, USA) using the 5′ reporter FAM™ dye-labeled and 3′ quencher Minor groove
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binder (MGB)-labeled probes (Applied Biosystems, Foster City, CA, USA). Gene expression level was
normalized to GAPDH endogenous control and analyzed according to the relative quantification method
(2−∆∆Ct). Three independent experiments were performed. Mean difference in gene expression between
p.Asp680Gly and the wild-type of the ADGRV1 were estimated by Student’s t-test. The p value < 0.05
was considered to indicate a statistically significant difference.
4. Results
By estimating the sequence quality along all sequences, 18.9 million reads 150 bp in read length
were produced from the patient sample. The % bases above average 30×were achieved for 99.2% of
the target region and the mean read depth (×) was 170 bp. Targeted exome sequencing identified a
heterozygous c.2039A>G of the ADGRV1 gene leading to a codon change of aspartic acid to glycine at
position 680 (NM_032119.3: c.2039A>G, p.Asp680Gly; rs547076322) had not been reported previously
to be related to afebrile and/or febrile seizures in the proband. To confirm the mutation segregated
with affected members, Sanger sequencing was conducted and revealed that this mutation as a
heterozygous state was present in the proband and her mother, respectively (Figure 2a). Cross-species
sequence comparisons (phastCons, SiPhy, and GERP) of amino acid sequences of ADGRV1 protein
revealed that this mutated site was highly conserved in vertebrates (phastCons 0.994 > cut-off of 0.8,
SiPhy 16.285 > 12.17, and GERP 5.87 > 4.4) [27]. The exome database of gnomAD showed a rare allele
frequency of 0.00002827. In addition, quantitative RT-PCR revealed that the expression of ADGRV1
mutant was weaker than that of the wild type (p = 0.048) (Figure 2b). Particularly, (likely) pathogenic
SCN1A mutations were not identified in this family.
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decreases the mRNA expression level of the ADGRV1, compared to the wild type (p = 0.048).
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5. Discussion
Seizures in FEB 4 are related to febrile episodes in childhood with no evidence of defined
pathologiccause or CNS infection. Simple FS is common, affecting 2–5% of children aged from 6
to 60 months. The tendency of developing epilepsy following simple FSs is not common. Complex FS is
characterized as focal onset, with a duration of >15 min, and/or >one seizure in 24 h and related to an
increased incidence of epilepsy. Channelopathies caused by mutation in ligand-gated or voltage-gated
channels lead to idiopathic epilepsies such as FS, benign neonatal or infantile epilepsy, and autosomal
dominant nocturnal frontal-lobe epilepsy. FEB 4 locus comprise the ADGRV1 gene, the causative gene
for audiogenic reflex seizures in the Frings mouse (Adgrv1) [28]. In this study, Avlgr1 (Algr1b, Algr1d, and
AVlgr1e) mRNA appeared dorminantly in the neuroepithelium of the developing mouse brain. Knockout
mice without exons 2–4 of Avlgr1b were prone to experience audiogenic reflex seizure, although obvious
cerebral histological abnormalities were not proven [29]. Differing from previous patients with ultra-rare
ADGRV1 variants [26,30], our patient showed febrile seizures with afebrile seizures.
To the best of our knowledge, we reported a first Korean family who showed FS and afebrile
seizures with ADGRV1 mutation, but without developmental delay/and or intellectual disability and the
seizure disappeared after 60 months without anti-seizure medication. The identified nucleotide change
in ADGRV1 replaces aspartic acid with glycine at position 680 of the ADGRV1 protein (p.Asp680Gly).
This protein’s glycine residue is highly conserved, and has not been reported for individuals with
ADGRV1-related FEB 4 (Table 1). In a previous study, mutation screening for the ADGRV1 detected
several missense mutations with allele frequency < 0.0005 in 48 families with FSs or afebrile seizures [26].
Although different missense mutations (p.Tyr674Cys and p.Val754Ala) at the near codons have been
predicted to be benign or pathogenic, the segregation of the mutation in our family supports its
pathogenicity as in autosomal dominant manner. However, this prediction has not been confirmed
by functional analysis, and the clinical manifestation of the observed mutation is certain only in
two-generation family members showing afebrile and febrile seizures. Thus, this ADGRV1 mutation
may be a candidate as a genetic cause of afebrile and febrile seizures in FEB 4.
On the other hand, ADGRV1 variation plays a part in developing epilepsy with myoclonic seizures,
although the inheritance manner may be different in various patients [30]. The function of ADGRV1
is unestablished, but multiple calcium exchanger b-repeats in the ectodomain imply a contribution
to protein–protein interaction that may be calcium mediated [31]. Particularly, the sequence of the
ADGRV1/VLGR1 gene harbors the same EAR (epilepsy-related repeat) domain located in the LGI1
(leucine-rich glioma-inactivated 1, 604619) gene which is a causative gene in autosomal dominant
lateral temporal lobe epilepsy with auditory features (ADLTE; 600512) [32]. ADGRV1 and LGI1
encode proteins that share a seven-fold repeated 44-residue motif homology domain, which has
been named an EAR domain (Figure 3a) [32]. Scheel et al. suggested that the EAR domain plays a
critical part in developing epilepsy by attaching to an unknown antiepileptic ligand or by interfering,
with synaptogenesis or axon guidance [32]. The pathogenesis of ADGRV1 haploinsufficiency leading to
seizures remains not well established, but animal studies have provided early insight into the nature of
the mechanism. Comprehending the signaling pathways downstream of aGPCRs is not only essential
for drug discovery, but also for achieving a fundamental understanding of receptor function [33].
ADGRV1, the largest aGPCR, has been found to couple to Gαi and signal to protein kinases A and C
via Gαq and Gαs (Figure 3b). Lobe-Philippot et al. reported that ADGRV1 is needed for GABAergic
interneuron development in the auditory cortex [34]. Dysfunction of cortical GABAnergic neurons
can be a potential epileptogenic mechanism in humans, thus it can be a therapeutic target. In this
family, the proband and her mother showed recurrent febrile seizures without other neurological
comorbidity, and the seizure disappeared after the age of 5 without anti-seizure medication. ADGRV1
can be a susceptible gene for the mutation that can lead to febrile and afebrile seizures. On the other
hand, whole-exome sequencing in combination with a genome-wide association study might be the
most straightforward way to get some insight into the genetics of FS, which addresses the issues of
phenocopies and genetic heterogeneity by sheer statistical power and sample size [35,36].
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Table 1. Results of in silico analysis of rare missense ADGRV1 mutations with allele frequency < 0.0005 reported by Myers KA et al. and this study.









Benign (0.001) Polymorphism Radical 194 −5.21 Calx-β5 Father


















































(0.996) Disease causing Conservative 58 5.78 Calx-β31 Father
* Identified in the present study. Reference sequence number: NM_032119.3 NP_115495.3. Abbreviations: rsID, reference ID in dbSNP; gnomAD, The Genome Aggregation Database;
EA, East Asian; EU, non-Finnish Europe; SA, South Asian; All, total population; Polyphen-2, Polymorphism Phenotyping v2;) AF (Allele Frequency); Grantham, Grantham scores for
conservative < 100; GERP, Genomic Evolutionary Rate Profiling for conservative > 4.4.
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6. Conclusions
ADGRV1 may be related to a range of self-limited, mild febrile or infantile seizure without
intellectual disability and developmental delay. ADGRV1 mutation may play an influential role in the
occurrence of genetic epilepsies, especially those with febrile and afebrile seizures. If children under
the age of 5 with no other neurological symptoms have febrile and other types of seizures, including
those with no fevers, the ADGRV1 test will be useful like other genetic testings in finding the causes
and prognosis of seizures. This may provide reassurance for the family towards an individual patient
based on their genetic profile instead of empirical trials of anti-seizure medication. Further research is
needed to establish an association between ADGRV1 mutations and febrile/afebrile seizures.
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